Renalytix plc announced that Howard Doran, who has served as the Company's Chief Business Officer since September 2023, has been appointed as President, effective April 30, 2024. Thomas McLain, who has served as the Company's President since July 2019, is stepping down effective that date.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
17.06 GBX | -2.51% |
|
+4.98% | +10.06% |
14/06 | Renalytix's Diabetes, Kidney Disease Test Gets Medicare Final Coverage Determination | MT |
14/06 | Renalytix Secures Medicare's Final Local Coverage Determination for Kidney Disease Test | MT |
![Consensus](/images/consensus_flch.gif)
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+10.06% | 3.43Cr | |
-27.01% | 1.61TCr | |
-50.73% | 243.17Cr | |
+27.80% | 201.96Cr | |
-7.88% | 153.25Cr | |
+25.95% | 128.8Cr | |
-19.07% | 93Cr | |
-32.38% | 77Cr | |
+0.22% | 76Cr | |
-26.15% | 62Cr |
- Stock Market
- Equities
- RENX Stock
- News Renalytix Plc
- Renalytix plc Announces Executive Changes, Effective from April 30, 2024